

## ULTRASIGHT ABSTRACT

### **1. Investment Rational**

UltraSight's real-time ultrasound guidance system aims to bring the benefits of cardiac imaging to more healthcare professionals in multiple care settings and allow patients easier access to cardiac treatment.

- Pivotal [study](#) completed; CE Mark and UKCA Mark granted (2022).
- Under US FDA 510(k) review.
- Won Bristol Meyers Squibb Improving Cardiovascular Disease Outcomes Challenge.
- In advanced discussions regarding a strategic partnership.

### **2. Business Strategy**

UltraSight plans to build a commercial organization for cardiac ultrasound echo systems. The technology will be deployed at walk-in clinics, community hospitals, etc., where patients can receive medical care locally, enabling lower-level medical staff to capture ultrasound images. UltraSight will provide support for acquisition of cardiac images which can be remotely accessed by expert cardiologists for interpretation and patient management.

### **3. Core Technology**

UltraSight AI-driven software provides real-time guidance and quality assessment to allow healthcare professionals, regardless of sonography proficiency, to consistently perform high-quality cardiac ultrasound in a variety of settings at the point of care, including clinics, community hospitals, ambulances, and remote and rural areas.

### **4. Product Profile/Pipeline \***

UltraSight's AI solution allows novice ultrasound users to acquire diagnostic-quality cardiac images where the patient is located which are then sent for remote image interpretation through telehealth systems. By separating the acquisition and interpretation of ultrasound images, UltraSight's technology promises to increase equitable access to cardiac care. This new care delivery model is referred to as *decentralized cardiac ultrasound monitoring*.

### **5. What's Next?**

Following FDA clearance of our product, we aim to build a commercial organization in the US to introduce our solution to the market with selected partners, in addition to completing our next fundraising round.

*\*UltraSight's real-time ultrasound guidance system is not FDA cleared or available for sale in the U.S. at this time.*